Ibrance
E474934
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
All labels observed (2)
| Label | Occurrences |
|---|---|
| palbociclib | 5 |
| Ibrance canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4850382 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ibrance Context triple: [Pfizer, developed, Ibrance]
-
A.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
B.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
C.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
D.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ibrance Target entity description: Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
A.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
B.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
C.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
D.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
CDK4/6 inhibitor
ⓘ
cancer medication ⓘ pharmaceutical drug ⓘ targeted therapy ⓘ |
| belongsToDrugClass |
antineoplastic agents
ⓘ
protein kinase inhibitors ⓘ |
| hasActiveIngredient |
palbociclib
ⓘ
linked to:
Ibrance
|
| hasAdministrationCycle | 28-day cycle ⓘ |
| hasATCCode | L01EF01 ⓘ |
| hasBlackBoxWarning | none ⓘ |
| hasCommonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ infections ⓘ leukopenia ⓘ nausea ⓘ neutropenia ⓘ stomatitis ⓘ thrombocytopenia ⓘ |
| hasCommonDoseStrength |
100 mg
ⓘ
125 mg ⓘ 75 mg ⓘ |
| hasDosageForm |
capsule
ⓘ
tablet ⓘ |
| hasDosingSchedule | 21 days on treatment followed by 7 days off ⓘ |
| hasFDAApprovalStatus | approved ⓘ |
| hasGenericName |
palbociclib
ⓘ
linked to:
Ibrance
|
| hasInitialFDAApprovalYear | 2015 ⓘ |
| hasINN |
palbociclib
ⓘ
linked to:
Ibrance
|
| hasPregnancyCategory | can cause fetal harm ⓘ |
| hasRegulatoryAgency |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| hasRouteOfAdministration | oral ⓘ |
| isApprovedFor |
men with HR-positive, HER2-negative advanced or metastatic breast cancer
ⓘ
postmenopausal women with HR-positive, HER2-negative advanced breast cancer ⓘ |
| isContraindicatedWith | severe hypersensitivity to palbociclib ⓘ |
| isIndicatedFor |
HER2-negative breast cancer
ⓘ
advanced breast cancer ⓘ hormone receptor–positive breast cancer ⓘ metastatic breast cancer ⓘ |
| isManufacturedBy | Pfizer ⓘ |
| isMetabolizedBy | CYP3A ⓘ |
| isTakenWithFood | yes ⓘ |
| isUsedInCombinationWith |
fulvestrant
ⓘ
letrozole ⓘ |
| mechanismOfAction | inhibits CDK4 and CDK6 to block cell cycle progression from G1 to S phase ⓘ |
| targets |
cyclin-dependent kinase 4
ⓘ
linked to:
CDK4
cyclin-dependent kinase 6 ⓘ
linked to:
CDK6
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ibrance Description of subject: Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Ibrance
linked to: Ibrance
linked to: Ibrance
linked to: Ibrance